Characteristics and immune responses of patients vaccinated in first remission after chemotherapy (n = 25)
| Patient . | Age/sex . | Histology, stage . | Chemotherapy, no. cycles . | Prevaccine tumor status . | DCs pulsed with . | No. DCs* . | Anti-Id response . | Follow-up after chemotherapy . | |
|---|---|---|---|---|---|---|---|---|---|
| T cell . | Ab . | ||||||||
| D11 | 65/M | FM, IVA | CHOP × 4 | RD | Id | 33 × 106 | − | − | SD, 51 mos |
| CVP/F × 4 | |||||||||
| D12 | 44/F | FSC, IVA | CVP × 8 | MRD | Id | 9 × 106 | + | − | PD at 15 mos, NED at 62 mos‡ |
| D13 | 53/F | FSC, IIIA | CVP × 8 | RD | Id | 19 × 106 | − | − | NED, 52 mos |
| D14 | 60/M | FSC, IIIA | CVP × 6 | NED | Id | 9 × 106 | − | − | NED, 53 mos |
| D15 | 30/M | FSC, IVB | CVP × 8 | MRD | Id | 19 × 106 | + | − | SD, 47 mos |
| D16 | 34/M | FSC, IIIA | CVP × 6 | MRD | Id | 11 × 106 | + | − | NED, 52 mos |
| D17 | 44/F | FSC, IVA | CVP/F × 8 | MRD | Id | 17 × 106 | − | +μ† | NED, 56 mos |
| D18 | 52/F | FSC, IVA | Chl × 6 | MRD | Id | 17 × 106 | + | − | NED, 43 mos |
| D19 | 60/F | FSC, IVA | CVP × 8 | MRD | Id | 14 × 106 | − | − | SD, 46 mos |
| D20 | 48/M | FSC, IVA | CVP × 6 | PD | Id | 18 × 106 | − | − | PD at 9 mos, alive at 50 mos |
| D21 | 38/M | FM, IVA | CVP × 6 | MRD | Id | 8 × 106 | + | − | PD at 25 mos, dead at 32 mos2-153 |
| D22 | 40/M | FSC, IVA | CVP × 8 | MRD | Id | 19 × 106 | − | − | PD at 35 mos, alive at 44 mos |
| D23 | 55/F | FSC, IVA | CVP × 8 | RD | Id-KLH | 15 × 106 | − | +μ† | SD, 39 mos |
| D24 | 47/F | FM, IVA | CVP × 6 | NED | Id-KLH | 16 × 106 | + | − | NED, 38 mos |
| D25 | 30/M | FSC, IVA | CVP × 6 | RD | Id-KLH | 10 × 106 | − | − | PD at 18 mos, alive at 37 mos |
| D26 | 56/M | FM, IVA | CVP × 7 | NED | Id-KLH | 16 × 106 | + | + | NED, 45 mos |
| D27 | 50/F | FM, IVA | CVP × 6 | PD | Id-KLH | 21 × 106 | − | − | PD at 9 mos,2-153 alive at 35 mos |
| D28 | 61/M | FM, IVA | CVP × 6 | NED | Id-KLH | 10 × 106 | + | − | PD at 21 mos, alive at 36 mos |
| D29 | 50/M | FSC, IVB | CVP × 8 | RD | Id-KLH | 12 × 106 | − | + | MRD, 28 mos |
| D30 | 50/F | FM, IVA | CVP × 6 | MRD | Id-KLH | 20 × 106 | − | − | SD, 24 mos |
| CHOP × 2 | |||||||||
| D31 | 54/F | FSC, IVA | CVP × 8 | NED | Id-KLH | 10 × 106 | − | + | NED, 24 mos |
| D32 | 43/F | FSC, IVA | CVP × 8 | MRD | Id-KLH | 15 × 106 | − | +μ† | PD at 16 mos, alive at 25 mos |
| D33 | 55/M | FM, IIIA | CVP × 7 | RD | Id-KLH | 21 × 106 | − | − | SD, 23 mos |
| CHOP × 4 | |||||||||
| D34 | 53/M | FSC, IVA | CVP × 6 | RD | Id-KLH | 35 × 106 | − | + | SD, 25 mos |
| CHOP × 2 | |||||||||
| D35 | 47/M | FSC, IVA | CVP × 8 | MRD | Id-KLH | 28 × 106 | + | − | PD at 28 mos, alive at 33 mos |
| Patient . | Age/sex . | Histology, stage . | Chemotherapy, no. cycles . | Prevaccine tumor status . | DCs pulsed with . | No. DCs* . | Anti-Id response . | Follow-up after chemotherapy . | |
|---|---|---|---|---|---|---|---|---|---|
| T cell . | Ab . | ||||||||
| D11 | 65/M | FM, IVA | CHOP × 4 | RD | Id | 33 × 106 | − | − | SD, 51 mos |
| CVP/F × 4 | |||||||||
| D12 | 44/F | FSC, IVA | CVP × 8 | MRD | Id | 9 × 106 | + | − | PD at 15 mos, NED at 62 mos‡ |
| D13 | 53/F | FSC, IIIA | CVP × 8 | RD | Id | 19 × 106 | − | − | NED, 52 mos |
| D14 | 60/M | FSC, IIIA | CVP × 6 | NED | Id | 9 × 106 | − | − | NED, 53 mos |
| D15 | 30/M | FSC, IVB | CVP × 8 | MRD | Id | 19 × 106 | + | − | SD, 47 mos |
| D16 | 34/M | FSC, IIIA | CVP × 6 | MRD | Id | 11 × 106 | + | − | NED, 52 mos |
| D17 | 44/F | FSC, IVA | CVP/F × 8 | MRD | Id | 17 × 106 | − | +μ† | NED, 56 mos |
| D18 | 52/F | FSC, IVA | Chl × 6 | MRD | Id | 17 × 106 | + | − | NED, 43 mos |
| D19 | 60/F | FSC, IVA | CVP × 8 | MRD | Id | 14 × 106 | − | − | SD, 46 mos |
| D20 | 48/M | FSC, IVA | CVP × 6 | PD | Id | 18 × 106 | − | − | PD at 9 mos, alive at 50 mos |
| D21 | 38/M | FM, IVA | CVP × 6 | MRD | Id | 8 × 106 | + | − | PD at 25 mos, dead at 32 mos2-153 |
| D22 | 40/M | FSC, IVA | CVP × 8 | MRD | Id | 19 × 106 | − | − | PD at 35 mos, alive at 44 mos |
| D23 | 55/F | FSC, IVA | CVP × 8 | RD | Id-KLH | 15 × 106 | − | +μ† | SD, 39 mos |
| D24 | 47/F | FM, IVA | CVP × 6 | NED | Id-KLH | 16 × 106 | + | − | NED, 38 mos |
| D25 | 30/M | FSC, IVA | CVP × 6 | RD | Id-KLH | 10 × 106 | − | − | PD at 18 mos, alive at 37 mos |
| D26 | 56/M | FM, IVA | CVP × 7 | NED | Id-KLH | 16 × 106 | + | + | NED, 45 mos |
| D27 | 50/F | FM, IVA | CVP × 6 | PD | Id-KLH | 21 × 106 | − | − | PD at 9 mos,2-153 alive at 35 mos |
| D28 | 61/M | FM, IVA | CVP × 6 | NED | Id-KLH | 10 × 106 | + | − | PD at 21 mos, alive at 36 mos |
| D29 | 50/M | FSC, IVB | CVP × 8 | RD | Id-KLH | 12 × 106 | − | + | MRD, 28 mos |
| D30 | 50/F | FM, IVA | CVP × 6 | MRD | Id-KLH | 20 × 106 | − | − | SD, 24 mos |
| CHOP × 2 | |||||||||
| D31 | 54/F | FSC, IVA | CVP × 8 | NED | Id-KLH | 10 × 106 | − | + | NED, 24 mos |
| D32 | 43/F | FSC, IVA | CVP × 8 | MRD | Id-KLH | 15 × 106 | − | +μ† | PD at 16 mos, alive at 25 mos |
| D33 | 55/M | FM, IIIA | CVP × 7 | RD | Id-KLH | 21 × 106 | − | − | SD, 23 mos |
| CHOP × 4 | |||||||||
| D34 | 53/M | FSC, IVA | CVP × 6 | RD | Id-KLH | 35 × 106 | − | + | SD, 25 mos |
| CHOP × 2 | |||||||||
| D35 | 47/M | FSC, IVA | CVP × 8 | MRD | Id-KLH | 28 × 106 | + | − | PD at 28 mos, alive at 33 mos |
FSC indicates follicular small cleaved cell; FM, follicular mixed small cleaved and large cell; F/DSC, follicular and diffuse small cleaved cell; CHOP, cyclophosphamide, adriamycin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; CVP/F, CVP alternating with fludarabine; Chl, chlorambucil; RD, residual disease; MRD, minimum residual disease; SD, stable disease; PD, progressive disease; NED, no clinical evidence of disease; Ab, antibody.
Total number of DCs infused over the course of 4 vaccinations.
IgM, but not IgG anti-Id antibodies detectable in serum.
Revaccinated with Id-KLH plus SAF adjuvant. See Table 3.
Histologic transformation to diffuse large cell lymphoma.